Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results.

Jason BacharachDavid L WirtaRobert Smyth-MedinaMichael S KorenfeldShane R KannarrShane FosterMark J JarosCharles B Slonim

Published in: Clinical ophthalmology (Auckland, N.Z.) (2021)

Oxymetazoline 0.1% provided rapid and sustained upper eyelid elevation. Together with data demonstrating superior visual field improvement and a favorable safety profile, this analysis supports oxymetazoline 0.1% as an effective non-surgical treatment for acquired ptosis.

Keyphrases

loop mediated isothermal amplification
double blind
open label
placebo controlled
phase iii
big data
machine learning
phase ii
study protocol
quantum dots